LP-10 (Oral Rinse)

About Lipella Pharmaceuticals

Lipella Pharmaceuticals leverages its proprietary liposomal delivery platform to develop targeted therapies for mucosal diseases where traditional treatments struggle. The company has a diversified pipeline with LP-10 in Phase 2 trials for oral lichen planus, hemorrhagic cystitis, and oral graft-versus-host disease, and LP-50 in preclinical development for bladder cancer. Their strategy focuses on repurposing proven drugs through the 505(b)(2) regulatory pathway to accelerate development and reduce risk.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals leverages its proprietary liposomal delivery platform to develop targeted therapies for mucosal diseases where traditional treatments struggle. The company has a diversified pipeline with LP-10 in Phase 2 trials for oral lichen planus, hemorrhagic cystitis, and oral graft-versus-host disease, and LP-50 in preclinical development for bladder cancer. Their strategy focuses on repurposing proven drugs through the 505(b)(2) regulatory pathway to accelerate development and reduce risk.

Therapeutic Areas